FDA approves Vifor's hyperphosphatemia drug

12/2/2013 | PharmaTimes (U.K.)

Vifor Pharma has obtained federal approval for its Velphoro therapy for hyperphosphatemia in patients with chronic kidney disease who are undergoing dialysis. Data from a Phase III trial showed the drug fared better than Sanofi's Renvela in regulating phosphorus accumulation in the bloodstream.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC